OBJECTIVE: To derive a risk score for the combination of death from all causes, myocardial infarction, and disabling stroke in patients with stable symptomatic angina who require treatment for angina and have preserved left ventricular function. DESIGN: Multivariate Cox regression analysis of data from a large multicentre trial. SETTING:Outpatient cardiology clinics in western Europe, Israel, Canada, Australia, and New Zealand. PARTICIPANTS: 7311 patients with all required data available. MAIN OUTCOME MEASURE: Death from any cause or myocardial infarction or disabling stroke during a mean follow-up of 4.9 years. RESULTS:1063 patients either died from any cause or sustained myocardial infarction or disabling stroke. The five year risk of this composite ranged from 4% for patients in the lowest tenth of risk to 35% for patients in the highest tenth. The risk score combines 16 routinely available clinical variables (in order of decreasing contribution): age, left ventricular ejection fraction, smoking, white blood cell count, diabetes, casual blood glucose concentration, creatinine concentration, previous stroke, at least one angina attack a week, coronary angiographic findings (if available), lipid lowering treatment, QT interval, systolic blood pressure > or = 155 mm Hg, number of drugs used for angina, previous myocardial infarction, and sex. Fitting the same model separately to all cause death, myocardial infarction, and stroke gave similar results. The risk score did not seem to predict the nature of the event (death in 39%, myocardial infarction in 46%, and disabling stroke in 15%) or the incidence of angiography or revascularisation, which occurred in 29% of patients. CONCLUSION: This risk score is an objective aid in deciding on further management of patients with stable angina with the aim of reducing serious outcome events. The score can also be used in planning future trials.
RCT Entities:
OBJECTIVE: To derive a risk score for the combination of death from all causes, myocardial infarction, and disabling stroke in patients with stable symptomatic angina who require treatment for angina and have preserved left ventricular function. DESIGN: Multivariate Cox regression analysis of data from a large multicentre trial. SETTING:Outpatient cardiology clinics in western Europe, Israel, Canada, Australia, and New Zealand. PARTICIPANTS: 7311 patients with all required data available. MAIN OUTCOME MEASURE: Death from any cause or myocardial infarction or disabling stroke during a mean follow-up of 4.9 years. RESULTS: 1063 patients either died from any cause or sustained myocardial infarction or disabling stroke. The five year risk of this composite ranged from 4% for patients in the lowest tenth of risk to 35% for patients in the highest tenth. The risk score combines 16 routinely available clinical variables (in order of decreasing contribution): age, left ventricular ejection fraction, smoking, white blood cell count, diabetes, casual blood glucose concentration, creatinine concentration, previous stroke, at least one angina attack a week, coronary angiographic findings (if available), lipid lowering treatment, QT interval, systolic blood pressure > or = 155 mm Hg, number of drugs used for angina, previous myocardial infarction, and sex. Fitting the same model separately to all cause death, myocardial infarction, and stroke gave similar results. The risk score did not seem to predict the nature of the event (death in 39%, myocardial infarction in 46%, and disabling stroke in 15%) or the incidence of angiography or revascularisation, which occurred in 29% of patients. CONCLUSION: This risk score is an objective aid in deciding on further management of patients with stable angina with the aim of reducing serious outcome events. The score can also be used in planning future trials.
Authors: Philip A Poole-Wilson; Jacobus Lubsen; Bridget-Anne Kirwan; Fred J van Dalen; Gilbert Wagener; Nicolas Danchin; Hanjörg Just; Keith A A Fox; Stuart J Pocock; Tim C Clayton; Michael Motro; John D Parker; Martial G Bourassa; Anthony M Dart; Per Hildebrandt; Ake Hjalmarson; Johannes A Kragten; G Peter Molhoek; Jan-Erik Otterstad; Ricardo Seabra-Gomes; Jordi Soler-Soler; Simon Weber Journal: Lancet Date: 2004 Sep 4-10 Impact factor: 79.321
Authors: Kim A Eagle; Michael J Lim; Omar H Dabbous; Karen S Pieper; Robert J Goldberg; Frans Van de Werf; Shaun G Goodman; Christopher B Granger; P Gabriel Steg; Joel M Gore; Andrzej Budaj; Alvaro Avezum; Marcus D Flather; Keith A A Fox Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: J Lubsen; P A Poole-Wilson; S J Pocock; F J van Dalen; J Baumann; B A Kirwan; A B Parker Journal: Eur Heart J Date: 1998-08 Impact factor: 29.983
Authors: M Justin Zaman; Cornelia Junghans; Neha Sekhri; Ruoling Chen; Gene S Feder; Adam D Timmis; Harry Hemingway Journal: CMAJ Date: 2008-09-23 Impact factor: 8.262
Authors: Laura P Kimble; Sandra B Dunbar; William S Weintraub; Deborah B McGuire; Sharon F Manzo; Ora L Strickland Journal: J Adv Nurs Date: 2011-02-24 Impact factor: 3.187
Authors: Ralph L Sacco; Minesh Khatri; Tatjana Rundek; Qiang Xu; Hannah Gardener; Bernadette Boden-Albala; Marco R Di Tullio; Shunichi Homma; Mitchell S V Elkind; Myunghee C Paik Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094
Authors: Harry Hemingway; Peter Philipson; Ruoling Chen; Natalie K Fitzpatrick; Jacqueline Damant; Martin Shipley; Keith R Abrams; Santiago Moreno; Kate S L McAllister; Stephen Palmer; Juan Carlos Kaski; Adam D Timmis; Aroon D Hingorani Journal: PLoS Med Date: 2010-06-01 Impact factor: 11.069
Authors: Martin Henriksson; Stephen Palmer; Ruoling Chen; Jacqueline Damant; Natalie K Fitzpatrick; Keith Abrams; Aroon D Hingorani; Ulf Stenestrand; Magnus Janzon; Gene Feder; Bruce Keogh; Martin J Shipley; Juan-Carlos Kaski; Adam Timmis; Mark Sculpher; Harry Hemingway Journal: BMJ Date: 2010-01-19